Daniel Busby
Stock Analyst at RBC Capital
(2.60)
# 2,061
Out of 5,163 analysts
6
Total ratings
66.67%
Success rate
22.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniel Busby
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRCA Verrica Pharmaceuticals | Downgrades: Sector Perform | $160 → $40 | $6.11 | +554.66% | 2 | May 25, 2022 | |
| PFE Pfizer | Maintains: Sector Perform | $43 → $44 | $26.58 | +65.54% | 1 | Jun 17, 2021 | |
| MNKD MannKind | Initiates: Sector Perform | $5 | $2.77 | +80.51% | 2 | May 14, 2021 | |
| ABBV AbbVie | Reiterates: Outperform | $135 | $219.68 | -38.55% | 1 | May 3, 2021 |
Verrica Pharmaceuticals
May 25, 2022
Downgrades: Sector Perform
Price Target: $160 → $40
Current: $6.11
Upside: +554.66%
Pfizer
Jun 17, 2021
Maintains: Sector Perform
Price Target: $43 → $44
Current: $26.58
Upside: +65.54%
MannKind
May 14, 2021
Initiates: Sector Perform
Price Target: $5
Current: $2.77
Upside: +80.51%
AbbVie
May 3, 2021
Reiterates: Outperform
Price Target: $135
Current: $219.68
Upside: -38.55%